arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Definium Therapeutics, Inc.

DFTX
$30.34 ▼ -2.38 (-7.26%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
25 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Neutral
auto_awesome

Analytical Summary

Definium Therapeutics, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Materials sector before making investment decisions.

Market Cap $3.4B
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -6.2% ↗
FCF / Share $-0.48 ↘
Trailing P/E —
Price / Book 4.4x
FCF Yield —
Debt / Equity 0.04
info Valuation on last close. End-of-day price, Nov 5, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-158.99M
↓ -271.9% —
FCF / Share Free cash flow per share
$-0.48
↓ -21.7% —
Long-Term Debt Long-term obligations
$36.47M
↓ -10.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
15
Financial Health →
50
Cash Quality ↑
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 25 quarters